- Home
- TOP vs ALGS Comparison
TOP vs ALGS Comparison
Compare TOP & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TOP | ALGS |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.2M | 34.6M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TOP | ALGS |
|---|---|---|
| Price | $2.23 | $4.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $39.33 |
| AVG Volume (30 Days) | ★ 434.5K | 117.1K |
| Earning Date | 01-20-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 81.25 | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,723,765.00 | $2,186,000.00 |
| Revenue This Year | N/A | $32.20 |
| Revenue Next Year | N/A | $4.71 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 41.89 | N/A |
| 52 Week Low | $0.61 | $4.60 |
| 52 Week High | $3.33 | $13.69 |
Technical Indicators
Market Signals| Indicator | TOP | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 55.79 | 27.71 |
| Support Level | $0.89 | N/A |
| Resistance Level | $2.88 | $6.91 |
| Average True Range (ATR) | 0.33 | 0.56 |
| MACD | -0.03 | -0.21 |
| Stochastic Oscillator | 40.16 | 0.81 |
Price Performance
Historical ComparisonAbout TOP TOP Financial Group Limited
TOP Financial Group Ltd is an online brokerage firm in Hong Kong specializing in trading local and overseas equities, futures, and options products. The Company generates brokerage commission income by enabling its customers to trade on multiple exchanges present globally. The company operates in only one segment which is the futures brokerage service.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.